(19)
(11) EP 3 586 852 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
28.04.2021 Bulletin 2021/17

(45) Mention of the grant of the patent:
31.03.2021 Bulletin 2021/13

(21) Application number: 19180127.3

(22) Date of filing: 10.01.2019
(51) International Patent Classification (IPC): 
A61K 35/17(2015.01)
A61K 39/00(2006.01)
C07K 16/30(2006.01)
 A61K 48/00(2006.01)
C07K 16/28(2006.01)
A61P 35/00(2006.01)

(54)

MODIFIED CELL EXPANSION AND USES THEREOF

MODIFIZIERTE ZELLEXPANSION UND VERWENDUNGEN DAVON

EXPANSION DE CELLULES MODIFIÉES ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 11.01.2018 US 201862616079 P
12.01.2018 US 201862616609 P
26.01.2018 US 201862622601 P
06.02.2018 US 201862626781 P
17.04.2018 US 201862659114 P
18.04.2018 US 201862659233 P
31.05.2018 US 201862678836 P
19.06.2018 US 201862687059 P
27.06.2018 US 201862690892 P
23.08.2018 US 201862721791 P
28.09.2018 US 201816146218

(43) Date of publication of application:
01.01.2020 Bulletin 2020/01

(62) Application number of the earlier application in accordance with Art. 76 EPC:
19700326.2 / 3544618

(73) Proprietors:
  • Innovative Cellular Therapeutics Inc.
    Rockville, MD 20850 (US)
  • Innovative Cellular Therapeutics Holdings, Ltd.
    Grand Cayman, KYI - 1104 (KY)

(72) Inventors:
  • XIAO, Lei
    Fengxian District, Shanghai 201203 (CN)
  • PU, Chengfei
    Fengxian District, Shanghai 201203 (CN)
  • CAO, Zhiyuan
    Fengxian District, Shanghai 201203 (CN)
  • WU, Zhao
    Fengxian District, Shanghai 201203 (CN)
  • MAO, Li
    Fengxian District, Shanghai 201203 (CN)
  • BI, Mao
    Fengxian District, Shanghai 201203 (CN)

(74) Representative: Abel & Imray 
Westpoint Building James Street West
Bath BA1 2DA
Bath BA1 2DA (GB)


(56) References cited: : 
WO-A1-2012/079000
 WO-A1-2017/149515
   
  • YOU FENGTAO ET AL: "Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells", SCIENCE CHINA LIFE SCIENCES, ZHONGGUO KEXUE ZAZHISHE, CHINA, vol. 59, no. 4, 7 March 2016 (2016-03-07), pages 386-397, XP035939690, ISSN: 1674-7305, DOI: 10.1007/S11427-016-5024-7 [retrieved on 2016-03-07]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).